Published in Blood Weekly, December 25th, 2003
The offering was first announced by Hemosol on November 7, 2003.
This new capital will help the company complete its ongoing nonclinical analysis of HEMOLINK.
The maximum size of the offering was 11,500,000 special warrants. Hemosol issued 7,841,800 special warrants at a purchase price of $0.75 per special warrant for gross proceeds of $5,881,350. Each special warrant will entitle the holder to acquire, at no additional cost, one common share and one-half of one...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.